



# **Zanamivir**

Catalog No: tcsc0631

J	Ţ	
		ĺ.

### **Available Sizes**

Size: 10mg

Size: 50mg

Size: 100mg



## **Specifications**

#### CAS No:

139110-80-8

#### Formula:

 $C_{12}H_{20}N_4O_7$ 

### **Pathway:**

Anti-infection

#### **Target:**

Influenza Virus

## **Purity / Grade:**

>98%

### **Solubility:**

 $H20 : \ge 33.33 \text{ mg/mL} (100.30 \text{ mM})$ 

### **Observed Molecular Weight:**

332.31

## **Product Description**

Zanamivir is an influenza viral **neuraminidase** inhibitor with  $IC_{50}$  values of 0.95 nM and 2.7 nM for influenza A and B, respectively.

IC50 & Target: IC50: 0.95 nM (Influenza A); 2.7 nM (Influenza B)<sup>[1]</sup>

#### In Vitro:





Zanamivir interacts with a group of amino acids in the active site of neuraminidase, which are conserved in all influenza A and B strains. Zanamivir blocks the action of neuraminidase, which prevents the cleavage of sialic acid on the cell receptors, thus preventing release and spread of the newly formed virions<sup>[2]</sup>.

In Vivo: Zanamivir has a poor bioavailability in oral administration, with only 4-17% of the agent. Oral delivery of zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl  $\beta$ -cyclodextrin could be used with zanamivir to enhance the intestinal permeability<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!